Involved-field radiotherapy for patients in partial remission after chemotherapy for advanced Hodgkin's lymphoma

Department of Radiotherapy, Radboud University Nijmegen, Nymegen, Gelderland, Netherlands
International Journal of Radiation OncologyBiologyPhysics (Impact Factor: 4.26). 02/2007; 67(1):19-30. DOI: 10.1016/j.ijrobp.2006.08.041
Source: PubMed


The use of radiotherapy in patients with advanced Hodgkin's lymphoma (HL) is controversial. The purpose of this study was to describe the role of radiotherapy in patients with advanced HL who were in partial remission (PR) after chemotherapy.
In a prospective randomized trial, patients <70 years old with previously untreated Stage III-IV HL were treated with six to eight cycles of mechlorethamine, vincristine, procarbazine, prednisone/doxorubicin, bleomycine, vinblastine hybrid chemotherapy. Patients in complete remission (CR) after chemotherapy were randomized between no further treatment and involved-field radiotherapy (IF-RT). Those in PR after six cycles received IF-RT (30 Gy to originally involved nodal areas and 18-24 Gy to extranodal sites with or without a boost).
Of 739 enrolled patients, 57% were in CR and 33% in PR after chemotherapy. The median follow-up was 7.8 years. Patients in PR had bulky mediastinal involvement significantly more often than did those in CR after chemotherapy. The 8-year event-free survival and overall survival rate for the 227 patients in PR who received IF-RT was 76% and 84%, respectively. These rates were not significantly different from those for CR patients who received IF-RT (73% and 78%) or for those in CR who did not receive IF-RT (77% and 85%). The incidence of second malignancies in patients in PR who were treated with IF-RT was similar to that in nonirradiated patients.
Patients in PR after six cycles of mechlorethamine, vincristine, procarbazine, prednisone/doxorubicine, bleomycine, vinblastine treated with IF-RT had 8-year event-free survival and overall survival rates similar to those of patients in CR, suggesting a definite role for RT in these patients.

Download full-text


Available from: Roberto Bortolus,
1 Follower
86 Reads
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: INTRODUÇÃO RADIOTERAPIA NO ESTADIAMENTO INICIAL -Estádios I e II O papel da radioterapia na abordagem do linfoma de Hodgkin (LH) é bem definido. O objetivo deste estudo é apresentar e situar a radioterapia no tratamento atual dessa entidade. O LH pode ser subdividido em grupos favoráveis e desfavoráveis ao tratamento, de acordo com o prognóstico; o primeiro apresenta melhores resultados na terapia combinada (quimioterapia -QT -e radioterapia -RT) quando comparados ao segundo. Neste, usar campos menores de irradiação (a tendência atual para radioterapia) não tem diferença na sobrevida. Em favoráveis no estádio inicial, doses menores de QT e RT são eficazes. Nos estágios III e IV em geral, a adição de RT apenas aumenta o tempolivrededoença,mas não asobrevida. Descritores: linfoma, doença de Hodgkin, radioterapia. The role played by radiotherapy in Hodgkin's Lymphoma (HL) is well defined. This study discusses its importance in the current treatment of this disease. HL can be subdivided into groups favorable and unfavorable to treatment, according to the prognosis. Combined therapy (chemotherapy -CT -and radiotherapy -RT) presents better results for the first group. In the second group, using narrower fields of irradiation (the current approach) implies in no difference in survival time rates. As for those favorable to treatment in initial stages of disease, smaller doses of CTand RTare efficacious. For stages III and IV in general, the use of combined therapy only increases the free-of-diseasetimespan, butnottheoverallsurvivaltime.
  • [Show abstract] [Hide abstract]
    ABSTRACT: The outcome of patients with Hodgkin's lymphoma (HL) has improved dramatically because of improvement of both chemotherapy and radiotherapy. The need for radiotherapy in the treatment of patients with HL has changed tremendously. At first, extensive radiation was the only treatment option; then limited irradiation was used in addition to chemotherapy. Whether chemotherapy alone can be sufficient remains to be determined. For patients with early-stage HL with or without risk factors, two to four cycles of relatively mild chemotherapy followed by radiotherapy limited to involved fields (20-30 Gy/10-15 fractions) is widely accepted. For patients with advanced-stage HL, powerful chemotherapy is indicated; when partial remission results, chemotherapy is followed by radiotherapy to residual abnormalities, using only a small margin. In the future, treatment will be tailored to individual patients based on prognostic factors (possibly including biologic markers) and accurate evaluation of response to treatment.
    Current Hematologic Malignancy Reports 07/2007; 2(3):151-60. DOI:10.1007/s11899-007-0021-3 · 2.20 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: In recent years, radiotherapy in patients with Hodgkin lymphoma has evolved considerably because of sophisticated imaging technologies and radiation delivery techniques. Even more recently, a new radiation field concept has emerged to ensure better normal tissue protection while preserving an excellent clinical outcome. The role of radiation therapy is also rapidly changing because the concept of a risk-adapted treatment strategy, in which combined-modality treatments were the order of the day, is now expanding into a concept of response-adapted treatments.
    Seminars in Radiation Onchology 08/2007; 17(3):206-22. DOI:10.1016/j.semradonc.2007.02.007 · 4.03 Impact Factor
Show more